Allworth Financial’s Theravance Biopharma TBPH Stock Holding History

Allworth Financial’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.7K	Buy	335 +94	+39%	+$1.56K	﹤0.01%	4049
2026 Q1	$3.91K	Sell	241 -33	-12%	-$584	﹤0.01%	4091
2025 Q4	$5.13K	Buy	274 +62	+29%	+$1.03K	﹤0.01%	3689
2025 Q3	$3.1K	Buy	212 +49	+30%	+$619	﹤0.01%	3804
2025 Q2	$1.8K	Buy	163 +120	+279%	+$1.17K	﹤0.01%	3753
2025 Q1	$411	Sell	43 -91	-68%	-$847	﹤0.01%	3732
2024 Q4	$1.25K	Buy	+134	New	+$1.22K	﹤0.01%	3329
2024 Q1	–	Sell	-178	Closed	-$2K	–	3682
2023 Q4	$2K	Buy	178 +165	+1,269%	+$1.66K	﹤0.01%	2681
2023 Q3	$113	Sell	13 -93	-88%	-$898	﹤0.01%	3336
2023 Q2	$1.1K	Hold	106	–	–	﹤0.01%	2700
2023 Q1	$1.15K	Buy	+106	New	+$1.12K	﹤0.01%	2621
2022 Q2	–	Sell	-1,130	Closed	-$11K	–	2802
2022 Q1	$11K	Hold	1,130	–	–	﹤0.01%	1469
2021 Q4	$12K	Buy	+1,130	New	+$9.85K	﹤0.01%	1337

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allworth Financial's TBPH Position: Q2 2026 in Review

Allworth Financial increased its Theravance Biopharma (TBPH) stake by 39% in Q2 2026, buying an estimated $1.56K and bringing the position to 335 shares worth $5.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4049.

Allworth Financial first reported a position in TBPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $12K in Q4 2021. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Allworth Financial held 335 shares of Theravance Biopharma worth $5.7K as of Q2 2026.
Allworth Financial bought 94 Theravance Biopharma shares in Q2 2026, an estimated $1.56K.
Theravance Biopharma made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4049 holding.
Allworth Financial first reported a position in Theravance Biopharma in Q4 2021 and has held it in 13 quarters since.
Allworth Financial's Theravance Biopharma position peaked at $12K in Q4 2021.
179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.